Overheard at a recent Congressional Hearing on the reliability of the global generic drug supply chain: “I think it is fascinating to watch what the private sector hospitals in the United States are doing…they formed a nonprofit called Civica Rx in response to persistent shortages of vital life-saving medicines…and they are doing direct contracting with trustworthy manufacturers…with long-term contracts…I think it’s a game-changer.”

– Rosemary Gibson, co-author of China Rx

It is with this spirit in mind that we celebrate Civica Rx's first birthday! We're thrilled to be able to share highlights of our collective progress so far.
We Thank Our Growing Membership

Today we thank three philanthropies and nearly 40 health system members, representing 1000 U.S. hospitals, for launching and becoming a part of Civica.

**INSIGHTS FROM OUR MEMBERS INFORM CIVICA’S STRATEGIES**

- **The Drug Selection Advisory Committee (DSAC)** develops Civica’s prioritized drug lists during formal workshops at representative health system locations. So far, Tier 1 and Tier 2 drug lists have formed the foundation of the 2019/2020 Civica portfolio.

- **The Medical Trends Advisory Committee (MTAC)** weighs in on drug lists and provides insights on trends in drugs, dosage and device developments. Specifically, MTAC weighs in on clinical utilization and decision-making criteria that would impact the drugs selected and their prioritization for manufacturing. MTAC also weighs in on the future state of drugs coming off of patent, which may change current utilization patterns of generic medications within the healthcare setting.
• **Health System Operations Leads** from all member organizations weigh in on Civica plans and processes, and provide insights into the engagement with potential supplier partners and the most effective ways to operationalize using Civica products within hospitals and health systems.

---

**We Thank Our Supplier Partners**

We are thrilled to be working with outstanding partners to bring the first Civica drugs to market. By partnering this way, we are able to get vital medicines to our member health systems this year, per plan.

---

**SHORT-TERM: UP TO 16 DRUGS IN 2019**

- **Xellia Pharmaceuticals:**
  - In production & packaging: Vancomycin & Daptomycin

- **Hikma:**
  - In production: 13/14 drugs this year

- **Exela Pharma Sciences:**
  - Contract signed: Sodium Bicarbonate

To view the Xellia press release click [here](#). To view the Hikma press release click [here](#).

Civica is pursuing a three-pronged product supply strategy to stabilize the supply of antibiotics, anesthetic agents, cardiac medications, pain management medications, and other essential sterile injectable medicines used in hospitals daily.
The strategy includes:

- **Working with multiple generic drug manufacturers** that have the US FDA approved manufacturing facilities and capacity to produce Civica labeled generic drugs, allowing manufacturers to re-enter the market or increase existing capacity. Civica recently announced its first partnerships and more partnering agreements have been signed and will be announced shortly.

- **Developing Abbreviated New Drug Applications (ANDAs)** for generic drugs and working with contract manufacturing organizations (CMOs) to produce Civica medications.

- **Acquiring and building Civica manufacturing facilities** using Civica’s ANDAs.

---

**First Deliveries Coming Soon!**

We have produced, packaged and labeled our first batches of Vancomycin, in partnership with Xellia, and are now building inventory at our 3PL warehouse! We are working through planned supply chain logistics and expect to have all systems in place for first “pilot” deliveries of Vancomycin.
1 gram to hospitals by the end of September/early October with others to follow shortly thereafter. **View Packaging Video.**

Members of Civica’s leadership team visited with Xellia Pharmaceuticals employees last week to thank them for their partnership and great work, and had the opportunity to see the first vials of Vancomycin 10 gram coming off of the line!
In Case You Missed It

- #ICYMI: Excerpts on Civica Rx from West Health’s Healthcare Costs Innovation Summit (3 mins). Panel session includes Civica Governing Board Members Shelley Lyford, President and Chief Executive Officer, West Health, the Gary and Mary West Foundation and the West Health Institute, John Arnold, Founder and Co-Chair of Arnold Ventures, and Dan Liljenquist, SVP and Chief Strategy Officer, Intermountain Healthcare and Chairman of the Board, Civica Rx.
- #ICYMI: Grand Opening of Civica’s Utah Headquarters

A Message from Martin VanTrieste, CEO

It has been my privilege to lead Civica Rx over the past year as we work together to do what is in the best interest of patients. On behalf of the Civica Board of Directors and team, I thank all of you who have become a
part of this incredibly innovative and promising endeavor. I also thank the Civica team. Recruiting the best in their fields has been a pleasure because each team member joined Civica to help achieve our collective mission of providing quality medicines that are available and affordable. This team has accomplished more in a short period of time than any other team I have had the privilege to observe.

With respect and gratitude - Martin